Merck to scrap COVID drug for hospitalized patients

Thursday, 15. April 2021 13:17

Merck & Co., Inc. unveiled on Thursday that it will stop the development of its MK-7110 drug, meant to be used as a treatment for hospitalized patients with COVID-19.

The company explained that it will, instead, allocate the resources into the third phase trial of the mild-to-moderate COVID therapeutic molnupiravir, which it is developing along with Ridgeback Biotherapeutics.

"We continue to make progress in the clinical development of our antiviral candidate molnupiravir. Data from the dose-finding portion of these studies are consistent with the mechanism of action and provide meaningful evidence for the antiviral potential of the 800 mg dose," Roy Baynes, senior vice president at Merck Research Laboratories stated. "Merck's commitment from the outset of the pandemic has been to deploy our expertise and capabilities where they can have the most impact," he added, explaining why the development of MK-7110 has been halted.

Related Links: Merck & Co. Inc.
Breaking the News / BU